ERBB2 gene, also known as HER2 gene, is targeted by a combination of anti-HER2 antibody drugs, pertuzumab and trastuzumab, which have demonstrated significant improvements in treatment outcomes in patients with various types of cancer, including HER2-positive breast cancer and gastric cancer [151,152]. The gene discussed is ERBB2; the disease is breast carcinoma.